Becton, Dickinson and Company $BDX Shares Acquired by Waycross Partners LLC

Key Points

• Waycross Partners increased its Becton, Dickinson and Company stake by 7.3% in the third quarter, adding 8,619 shares to reach 127,154 shares valued at about $22.8 million.
• BD reported quarterly earnings of $4.15 per share and revenue of $5.27 billion, exceeding analyst estimates; revenue grew 5.4% year over year.
• The company authorized repurchases of up to 10 million shares and raised its quarterly dividend to $1.06, though concerns about its fiscal 2027 revenue-growth outlook weighed on the positive news.

Waycross Partners LLC boosted its position in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 7.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 127,154 shares of the medical instruments supplier's stock after acquiring an additional 8,619 shares during the period. Becton, Dickinson and Company accounts for 1.8% of Waycross Partners LLC's portfolio, making the stock its 26th largest position. Waycross Partners LLC's holdings in Becton, Dickinson and Company were worth $22,761,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in BDX. Maryland Capital Advisors Inc. raised its holdings in Becton, Dickinson and Company by 13,900.0% during the 3rd quarter. Maryland Capital Advisors Inc. now owns 140 shares of the medical instruments supplier's stock worth $25,000 after purchasing an additional 139 shares during the last quarter. Trifecta Capital Advisors LLC lifted its position in Becton, Dickinson and Company by 59.0% during the 3rd quarter. Trifecta Capital Advisors LLC now owns 167 shares of the medical instruments supplier's stock valued at $30,000 after purchasing an additional 62 shares during the period. Meeder Asset Management Inc. boosted its stake in shares of Becton, Dickinson and Company by 152.2% in the 1st quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier's stock valued at $27,000 after purchasing an additional 102 shares during the last quarter. Main Street Group LTD bought a new position in shares of Becton, Dickinson and Company in the 1st quarter valued at about $29,000. Finally, Bell Investment Advisors Inc acquired a new stake in shares of Becton, Dickinson and Company during the 2nd quarter worth approximately $29,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Trading Down 0.6%

Shares of BDX stock traded down $1.28 on Friday, reaching $212.27. The company had a trading volume of 2,172,550 shares, compared to its average volume of 1,599,485. The stock has a market cap of $58.49 billion, a PE ratio of 51.27, a PEG ratio of 13.39 and a beta of 0.22. The company has a 50-day moving average of $188.17 and a 200-day moving average of $170.28. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55. Becton, Dickinson and Company has a 12 month low of $137.35 and a 12 month high of $214.88.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its earnings results on Thursday, November 5th. The medical instruments supplier reported $4.15 earnings per share for the quarter, topping the consensus estimate of $4.07 by $0.08. The firm had revenue of $5.27 billion for the quarter, compared to analyst estimates of $5.11 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%. The company's revenue for the quarter was up 5.4% on a year-over-year basis. During the same period in the previous year, the company posted $3.96 earnings per share. On average, equities analysts forecast that Becton, Dickinson and Company will post 13.24 earnings per share for the current year.

Becton, Dickinson and Company announced that its board has initiated a share buyback plan on Thursday, November 5th that allows the company to repurchase 10,000,000 shares. This repurchase authorization allows the medical instruments supplier to reacquire up to 3.6% of its shares through open market purchases. Share repurchase plans are typically an indication that the company's board believes its stock is undervalued.

Becton, Dickinson and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 31st. Shareholders of record on Thursday, December 10th will be paid a $1.06 dividend. This is an increase from Becton, Dickinson and Company's previous quarterly dividend of $1.05. This represents a $4.24 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date is Thursday, December 10th. Becton, Dickinson and Company's dividend payout ratio is 126.51%.

Insider Activity

In related news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the firm's stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the completion of the sale, the chief executive officer directly owned 110,163 shares in the company, valued at approximately $20,380,155. This trade represents a 3.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Feld sold 165 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total value of $31,100.85. Following the transaction, the executive vice president owned 19,720 shares of the company's stock, valued at $3,717,022.80. The trade was a 0.83% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 6,907 shares of company stock valued at $1,269,128 in the last quarter. Company insiders own 0.40% of the company's stock.

Key Headlines Impacting Becton, Dickinson and Company

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: BD reported Q4 adjusted earnings of $4.15 per share and revenue of $5.27 billion, topping analyst expectations; revenue rose 5.4% year over year. BD fiscal 2026 results
• Positive Sentiment: The board raised the quarterly dividend 1% to $1.06 per share and authorized repurchases of up to 10 million shares, or about 3.6% of shares outstanding. Dividend increase and share repurchase authorization
• Positive Sentiment: Citigroup raised its price target to $241 and assigned a “buy” rating; Evercore ISI also lifted its target, to $230 from $210. Citigroup analyst rating Evercore ISI price target
• Neutral Sentiment: RBC raised its target to $225 but kept a “sector perform” rating, while Piper Sandler raised its target to $200 and maintained “neutral”—below the stock’s recent trading level. RBC analyst rating Piper Sandler price target
• Negative Sentiment: The main concern is the fiscal 2027 outlook: coverage reports say revenue-growth guidance came in just below expectations, tempering the impact of the Q4 beat and prompting investor concern. Fiscal 2027 guidance coverage

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on BDX shares. Stifel Nicolaus set a $195.00 price target on shares of Becton, Dickinson and Company in a research note on Friday, August 7th. Weiss Ratings raised shares of Becton, Dickinson and Company from a "hold (c-)" rating to a "hold (c)" rating in a research note on Wednesday. TD Cowen lifted their target price on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a "hold" rating in a report on Wednesday, August 5th. Bank of America upped their target price on shares of Becton, Dickinson and Company from $185.00 to $200.00 and gave the company a "neutral" rating in a research report on Monday, August 31st. Finally, Royal Bank Of Canada increased their price target on Becton, Dickinson and Company from $190.00 to $225.00 and gave the company a "sector perform" rating in a research note on Friday. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, eight have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $193.67.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops and manufactures products used in healthcare, clinical laboratories and life sciences research. Founded in 1897, the company has a long history of producing medical devices and supplies.

BD's products include syringes, needles, infusion systems and medication-management technologies, as well as equipment and supplies for collecting and processing clinical specimens. The company also provides diagnostic systems, laboratory instruments and tools used in areas such as cell analysis and biomedical research.

Its offerings serve hospitals, clinics, laboratories, researchers and pharmaceutical companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.